Cargando…

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease

PURPOSE OF THE REVIEW: Idiopathic inflammatory myopathies are a heterogeneous group of autoimmune disorders. The presence of different autoantibodies allows clinicians to define distinct phenotypes. Antibodies against the melanoma differentiation-associated protein 5 gene, also called anti-MDA5 anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selva-O’Callaghan, A., Romero-Bueno, F., Trallero-Araguás, E., Gil-Vila, A., Ruiz-Rodríguez, J. C., Sánchez-Pernaute, O., Pinal-Fernández, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Other CTD: Inflammatory Myopathies and Sjogren’s (I Pinal-Fernandez, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476986/ https://www.ncbi.nlm.nih.gov/pubmed/34603940 http://dx.doi.org/10.1007/s40674-021-00186-x

Ejemplares similares

Management of Cancer-Associated Myositis
por: Selva-O’Callaghan, Albert, et al.
Publicado: (2022)

Exercise in Myositis
por: Alexanderson, Helene
Publicado: (2018)

Current Treatment for Myositis
por: Barsotti, Simone, et al.
Publicado: (2018)

Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies
por: Qin, Li, et al.
Publicado: (2021)

Idiopathic inflammatory myopathies and hypertension: Possible involvement of hormonal factors
por: Armanini, Decio, et al.
Publicado: (2021)

Novel myosin-based therapies for congenital cardiac and skeletal myopathies
por: Ochala, Julien, et al.
Publicado: (2016)

Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry‐Based Study
por: Espinosa‐Ortega, Fabricio, et al.
Publicado: (2022)

Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
por: Labrador-Horrillo, Moises, et al.
Publicado: (2014)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

Mixed‐Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients
por: Hackett, Katie L., et al.
Publicado: (2018)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia()
por: Sanchez-Pernaute, Olga, et al.
Publicado: (2021)

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
por: Rose, Thomas, et al.
Publicado: (2016)

Familial Risk of Sjögren's Syndrome and Co‐aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study
por: Kuo, Chang‐Fu, et al.
Publicado: (2015)

Epigenetic Signatures of Salivary Gland Inflammation in Sjögren's Syndrome
por: Cole, Michael B., et al.
Publicado: (2016)

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy
por: Bezzina, Oriana M., et al.
Publicado: (2017)

Health-related quality of life and depression among participants in the Sjögren’s International Collaborative Clinical Alliance registry
por: Chou, Annie, et al.
Publicado: (2017)

Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity
por: Hammitt, Katherine M, et al.
Publicado: (2017)

Hospitalisation rates among patients with primary Sjögren’s syndrome: a population-based study, 1995–2016
por: Maciel, Gabriel, et al.
Publicado: (2018)

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome
por: Nayar, Saba, et al.
Publicado: (2019)

Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren’s syndrome and non-autoimmune sicca
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome
por: Pringle, Sarah, et al.
Publicado: (2018)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

Salivary gland ultrasound abnormalities in primary Sjögren’s syndrome: consensual US-SG core items definition and reliability
por: Jousse-Joulin, Sandrine, et al.
Publicado: (2017)

Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome
por: Hackett, Kate L, et al.
Publicado: (2019)

Cigarette smoking patterns preceding primary Sjögren’s syndrome
por: Mofors, Johannes, et al.
Publicado: (2020)

Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG
por: Bende, Richard J., et al.
Publicado: (2020)

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
por: Hillen, Maarten R, et al.
Publicado: (2020)

Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma
por: Pontarini, Elena, et al.
Publicado: (2020)

Antigen-driven selection of antibodies against SSA, SSB and the centromere ‘complex’, including a novel antigen, MIS12 complex, in human salivary glands
por: Takeshita, Masaru, et al.
Publicado: (2020)

Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero
por: Hedlund, Malin, et al.
Publicado: (2020)

Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren’s syndrome
por: Björk, Albin, et al.
Publicado: (2020)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome
por: van Nimwegen, Jolien F., et al.
Publicado: (2020)

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
por: Posada, James, et al.
Publicado: (2020)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Application of the OMERACT Grey-scale Ultrasound Scoring System for salivary glands in a single-centre cohort of patients with suspected Sjögren’s syndrome
por: Fana, Viktoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ka10jgp6s6l4qag9a069gbvjod